These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 36550750)

  • 1. JAK-STAT signalling shapes the NF-κB response in CLL towards venetoclax sensitivity or resistance via Bcl-XL.
    Haselager MV; Thijssen R; Bax D; Both D; De Boer F; Mackay S; Dubois J; Mellink C; Kater AP; Eldering E
    Mol Oncol; 2023 Jun; 17(6):1112-1128. PubMed ID: 36550750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL.
    Haselager M; Thijssen R; West C; Young L; Van Kampen R; Willmore E; Mackay S; Kater A; Eldering E
    Cell Death Differ; 2021 May; 28(5):1658-1668. PubMed ID: 33495554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.
    Asslaber D; Wacht N; Leisch M; Qi Y; Maeding N; Hufnagl C; Jansko B; Zaborsky N; Villunger A; Hartmann TN; Greil R; Egle A
    Clin Cancer Res; 2019 Mar; 25(6):1901-1912. PubMed ID: 30487125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.
    Haselager MV; Kielbassa K; Ter Burg J; Bax DJC; Fernandes SM; Borst J; Tam C; Forconi F; Chiodin G; Brown JR; Dubois J; Kater AP; Eldering E
    Blood; 2020 Dec; 136(25):2918-2926. PubMed ID: 32603412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STAT3 and NF-κB cooperatively control in vitro spontaneous apoptosis and poor chemo-responsiveness in patients with chronic lymphocytic leukemia.
    Liu FT; Jia L; Wang P; Wang H; Farren TW; Agrawal SG
    Oncotarget; 2016 May; 7(22):32031-45. PubMed ID: 27074565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leflunomide induces apoptosis in fludarabine-resistant and clinically refractory CLL cells.
    Dietrich S; Krämer OH; Hahn E; Schäfer C; Giese T; Hess M; Tretter T; Rieger M; Hüllein J; Zenz T; Ho AD; Dreger P; Luft T
    Clin Cancer Res; 2012 Jan; 18(2):417-31. PubMed ID: 22072733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
    Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
    Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells.
    Godbersen JC; Humphries LA; Danilova OV; Kebbekus PE; Brown JR; Eastman A; Danilov AV
    Clin Cancer Res; 2014 Mar; 20(6):1576-89. PubMed ID: 24634471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electron transport chain and mTOR inhibition synergistically decrease CD40 signaling and counteract venetoclax resistance in chronic lymphocytic leukemia.
    Chen Z; Cretenet G; Carnazzo V; Simon-Molas H; Kater AP; Windt GJWV; Eldering E
    Haematologica; 2024 Jan; 109(1):151-162. PubMed ID: 37439352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies.
    Melvold K; Giliberto M; Karlsen L; Ayuda-Durán P; Hanes R; Holien T; Enserink J; Brown JR; Tjønnfjord GE; Taskén K; Skånland SS
    Mol Oncol; 2022 Mar; 16(5):1153-1170. PubMed ID: 34861096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis.
    Dong QG; Sclabas GM; Fujioka S; Schmidt C; Peng B; Wu T; Tsao MS; Evans DB; Abbruzzese JL; McDonnell TJ; Chiao PJ
    Oncogene; 2002 Sep; 21(42):6510-9. PubMed ID: 12226754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax.
    Avsec D; Škrlj Miklavčič M; Burnik T; Kandušer M; Bizjak M; Podgornik H; Mlinarič-Raščan I
    Cell Death Dis; 2022 Oct; 13(10):860. PubMed ID: 36209148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas.
    Lee TL; Yeh J; Friedman J; Yan B; Yang X; Yeh NT; Van Waes C; Chen Z
    Int J Cancer; 2008 May; 122(9):1987-98. PubMed ID: 18172861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering.
    Tromp JM; Tonino SH; Elias JA; Jaspers A; Luijks DM; Kater AP; van Lier RA; van Oers MH; Eldering E
    Oncogene; 2010 Sep; 29(36):5071-82. PubMed ID: 20581863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of NF-κB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli to induce apoptosis in chronic lymphocytic leukemia cells.
    Cosimo E; McCaig AM; Carter-Brzezinski LJ; Wheadon H; Leach MT; Le Ster K; Berthou C; Durieu E; Oumata N; Galons H; Meijer L; Michie AM
    Clin Cancer Res; 2013 May; 19(9):2393-405. PubMed ID: 23532892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells.
    Horie R; Watanabe M; Okamura T; Taira M; Shoda M; Motoji T; Utsunomiya A; Watanabe T; Higashihara M; Umezawa K
    Leukemia; 2006 May; 20(5):800-6. PubMed ID: 16525497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CUDC-907 blocks multiple pro-survival signals and abrogates microenvironment protection in CLL.
    Chen Y; Peubez C; Smith V; Xiong S; Kocsis-Fodor G; Kennedy B; Wagner S; Balotis C; Jayne S; Dyer MJS; Macip S
    J Cell Mol Med; 2019 Jan; 23(1):340-348. PubMed ID: 30353642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells.
    Pickering BM; de Mel S; Lee M; Howell M; Habens F; Dallman CL; Neville LA; Potter KN; Mann J; Mann DA; Johnson PW; Stevenson FK; Packham G
    Oncogene; 2007 Feb; 26(8):1166-77. PubMed ID: 16924235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine modulation of nuclear factor-kappaB activity in B-chronic lymphocytic leukemia.
    Zaninoni A; Imperiali FG; Pasquini C; Zanella A; Barcellini W
    Exp Hematol; 2003 Mar; 31(3):185-90. PubMed ID: 12644014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human T-cell leukemia virus type I tax protein induces the expression of anti-apoptotic gene Bcl-xL in human T-cells through nuclear factor-kappaB and c-AMP responsive element binding protein pathways.
    Mori N; Fujii M; Cheng G; Ikeda S; Yamasaki Y; Yamada Y; Tomonaga M; Yamamoto N
    Virus Genes; 2001 Jun; 22(3):279-87. PubMed ID: 11450946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.